Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: Review and meta-analysis by Morgado, Manuel et al.
Practice rePorts Pharmacist interventions
241Am J Health-Syst Pharm—Vol 68  Feb 1, 2011
Pharmacist interventions to enhance blood pressure 
control and adherence to antihypertensive therapy: 
Review and meta-analysis
Manuel P. Morgado, Sandra r. Morgado, liliana C. MendeS, luíSa J. Pereira,  
and Miguel CaStelo-BranCo
Manuel P. Morgado, M.Sc., PharM.D., is Pharmacist, Health Sci-
ences Research Centre, University of Beira Interior (UBI), Covilhã, 
Portugal, and Senior Hospital Pharmacist, Hospital Centre of Cova 
da Beira (HCCB), Covilhã. Sandra r. Morgado, M.Sc., PharM.D., 
is Senior Hospital Pharmacist, HCCB. liliana c. MendeS, M.Sc., 
PharM.D., is a Ph.D. student, Health Sciences Research Centre, UBI. 
luíSa J. Pereira, Ph.D., is Mathematician and Statistician, Math-
ematics Department, UBI. Miguel caStelo-Branco, Ph.D., M.D., is 
Researcher, Health Sciences Research Centre, UBI, and Chief, Internal 
Medicine, HCCB.
Address correspondence to Dr. Morgado at the Health Sciences 
Research Centre, University of Beira Interior, Avenue Infante D. 
Henrique, Covilhã 6200-506, Portugal (manuelaugustomorgado@
gmail.com).
Supported by fellowship grant SFRH/BD/36756/2007 from the 
Fundação para a Ciência e a Tecnologia.
The authors have declared no potential conflicts of interest.
Copyright © 2011, American Society of Health-System Pharma-
cists, Inc. All rights reserved. 1079-2082/11/0201-0241$06.00.
DOI 10.2146/ajhp090656
Purpose. Pharmacist interventions to 
enhance blood pressure (BP) control and 
adherence to antihypertensive therapy in 
adults with essential hypertension were 
reviewed. 
Methods. A literature search was con-
ducted to identify relevant articles describ-
ing pharmacist interventions intended to 
improve adherence to antihypertensive 
medications. Studies were included if they 
described a pharmacist intervention to 
improve medication adherence and ana-
lyzed adherence to therapy and BP control 
as outcomes. A fixed-effects model was 
used to combine data from randomized 
controlled trials.
Results. A total of 15 studies were identi-
fied, testing 16 different interventions 
and containing data on 3280 enrolled 
patients. Although 87.5% of the interven-
tions resulted in significant improvements 
in treatment outcomes, only 43.8% of the 
interventions were associated with signifi-
cant increases in medication adherence. All 
interventions that increased antihyperten-
sive medication adherence also significant-
ly reduced BP. Almost all the interventions 
that were effective in increasing adherence 
to medication were complex, including 
combinations of different strategies. Meta-
analysis of 2619 patients in 8 studies found 
that pharmacist interventions significantly 
reduced systolic blood pressure (SBP) (p < 
0.001) and diastolic blood pressure (DBP) 
(p = 0.002) and that the meta-analytic dif-
ferences in SBP and DBP changes from 
baseline to endpoint in intervention and 
control groups were –4.9 ± 0.9 mm Hg 
(p < 0.001) and –2.6 ± 0.9 mm Hg (p < 0.001), 
respectively.
Conclusion. A literature review and meta-
analysis showed that pharmacist interven-
tions can significantly improve medication 
adherence, SBP, DBP, and BP control in 
patients with essential hypertension. Inter-
ventions were complex and multifaceted 
and included medication management in 
all analyzed studies. 
Index terms: Blood pressure; Compliance; 
Hypertension; Hypotensive agents; Inter-
ventions; Patients; Pharmacists
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Hypertension is a major risk fac-tor for cardiovascular disease and an important public health 
problem worldwide. The risk of car-
diovascular morbidity and mortality 
is particularly marked when there is 
insufficient hypertension control and 
prevention at the community level. 
Randomized controlled trials (RCTs) 
have demonstrated that treating high 
blood pressure (BP) with medication 
can substantially reduce the risk of 
stroke by 35–40% and myocardial 
infarction by 20–25%.1,2 Although 
the treatment of hypertension has 
been shown to reduce the risk of 
cardiovascular disease and mortality, 
hypertension remains inadequately 
managed worldwide, with a lack of 
adherence to BP-lowering medica-
tion playing a major role in poor 
BP control.3-7 Hypertensive patients 
may fail to take their medication 
because of the symptomless nature 
of the condition, the long duration 
of therapy, adverse effects of medi-
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cation, complicated drug regimens, 
the lack of understanding about 
hypertension management, costs 
of medication, and the challenge to 
individual patients’ health beliefs.8,9 
Adherence rates to antihypertensive 
agents differ depending on the popu-
lation studied, ranging between 50% 
and 70%.5,10,11
The importance of improving 
adherence to antihypertensive medi-
cation has been addressed by the 
seventh report of the Joint National 
Committee on Prevention, Detec-
tion, Evaluation, and Treatment of 
High Blood Pressure, emphasizing 
the role of all health care profession-
als, including pharmacists, to im-
prove adherence to treatment.1 In the 
past two decades, pharmacists have 
been developing and implementing 
validated methods and services to 
improve adherence to antihyperten-
sive medication and the clinical out-
comes of this “silent” disease.12
One systematic review, which 
included studies from 1978 to 2006, 
assessed pharmacist interventions 
in hypertensive patients in order to 
enhance patients’ adherence to medi-
cation and reduce systolic BP (SBP) 
and diastolic BP (DBP).13 Since then, 
several important RCTs14-17 and 
non-RCTs18-20 have been conducted 
to assess the effect of pharmacist 
interventions on medication adher-
ence and BP control in hypertensive 
patients.
While there is strong evidence 
supporting the benefits of antihyper-
tensive drug therapy,21 there is little 
clear evidence as to which types of 
pharmacist interventions for hyper-
tensive patients are most effective 
for increasing medication adherence 
and improving hypertension control. 
We conducted a systematic review of 
published data on pharmacist inter-
ventions targeting antihypertensive 
medication adherence in adults with 
essential hypertension to evaluate the 
effect of pharmacist interventions on 
antihypertensive medication adher-
ence and quantify the reductions in 
SBP and DBP resulting from those 
interventions. 
Methods
A literature search to identify 
pharmacist interventions intended 
to improve adherence to antihyper-
tensive medications and BP control 
was conducted. To be included in the 
systematic review, studies had to (1) 
have a population of adults with es-
sential hypertension currently treated 
with BP-lowering drugs in a primary 
care, an outpatient, or a commu-
nity setting, (2) clearly describe and 
evaluate an intervention delivered by 
a pharmacist to improve adherence 
with antihypertensive drugs and BP 
control, and (3) include both adher-
ence to antihypertensive medication 
and mean SBP, mean DBP, or BP con-
trol as outcomes. Studies describing 
multidisciplinary interventions were 
included only if the pharmacist’s 
role in patient care was clearly de-
scribed. Articles describing different 
health conditions (e.g., cardiovascu-
lar diseases not involving essential 
hypertension) were excluded, as were 
studies assessing SBP and DBP or 
BP control but not antihypertensive 
medication adherence. The criteria 
used to assess adherence and treat-
ment outcome were based on the 
observation that studies showing an 
increase in adherence without an im-
provement in clinical outcome pro-
vide no practical guidance for prac-
tice. Articles were also required to be 
written in English, French, Spanish, 
German, Portuguese, or Italian.
We searched the main electronic 
databases freely available in our 
research center: MEDLINE, The 
Cochrane Library, and ISI Web of 
Knowledge. Each database was inde-
pendently searched by two reviewers 
for articles published from January 
1999 through June 2009, using the 
terms high blood pressure, hyper-
tension, pharmaceutical services or 
pharmaceutical care or pharmacist, 
and patient outcomes (i.e., adherence, 
compliance, systolic blood pressure, di-
astolic blood pressure, and blood pres-
sure control). We also hand searched 
bibliographies of all retrieved articles 
to identify additional publications of 
pharmacist interventions on patient 
medication adherence.
Two authors independently se-
lected articles by first reading titles, 
then abstracts, and, finally, full texts. 
The reviewers selected articles based 
on the predefined inclusion and ex-
clusion criteria and then compared 
results. Any disagreements were 
resolved by consensus. The rationale 
for decisions was discussed until re-
viewers agreed on the final decision. 
A third author was called to resolve 
any remaining discrepancies con-
cerning article eligibility.
Data extraction was also per-
formed by two independent authors, 
and disagreements were resolved 
through the same consensus process 
used with article selection. The fol-
lowing data were obtained in dupli-
cate and verified: year of publication, 
study design, use of a comparison 
group, type of pharmacist interven-
tions, extent of follow-up, study set-
ting, sample size of both intervention 
and control groups, patients lost to 
follow-up, methods used to measure 
medication adherence, and out-
comes measured. The outcomes of 
particular interest were medication 
adherence, SBP, DBP, and BP control. 
During data extraction, we wrote 
to corresponding authors of studies 
to request missing data and clarify 
study details.
After data were extracted, we clas-
sified study outcomes as either sensi-
tive or nonsensitive. Sensitive results 
were those that were influenced posi-
tively by the pharmacist intervention 
from a clinical point of view and that 
had statistical significance (i.e., p of 
≤0.05 at the endpoint of the study). 
Pharmacist interventions aimed to 
increase adherence to BP-lowering 
medication and BP control were 
classified as (1) medication manage-
ment (drug therapy monitoring and 
adjustments; simplification of anti-
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hypertensive regimens; optimization 
of drug regimen in order to solve 
adverse drug reactions, drug–drug 
interactions, and food–drug inter-
actions; generic substitution), (2) 
educational interventions directed at 
the patient (hypertension education, 
BP self-monitoring recommenda-
tion, lifestyle education and coun-
seling, medication education and 
counseling), (3) self-monitoring and 
recording of BP, including educa-
tion, encouragement, and validata-
tion of BP monitor, (4) medication 
reminders, including education and 
counseling tips (adherence aids), 
and appointment reminders (e.g., 
telephone or computer-based), (5) 
improved administration systems 
(e.g., Medication Event Monitoring 
System [Aardex Group Ltd., Slon, 
Valais, Switzerland]), and medica-
tions dispensed using an adherence 
aid (e.g., blister packs), (6) more-
frequent follow-up appointments 
or contacts, (7) educational inter-
ventions and alerts directed at the 
health care professional (personal, 
telephone- or computer-based), 
and (8) pharmacist clinical visits 
in medical, university, hospital, and 
community-based clinics.
Two reviewers assessed the quality 
of accepted studies independently 
and in duplicate, using the quality 
scale of Downs and Black,22 which 
was developed based on epide-
miologic principles, reviews of study 
designs, and existing checklists for 
assessing RCTs. Disagreements re-
garding study quality were handled 
by consensus, and additional in-
formation about study design was 
requested from the authors if nec-
essary. The method of Downs and 
Black22 has been validated, and it 
allows for the scoring of quality of 
RCTs and observational studies. The 
instrument consists of a 28-item 
checklist that addresses a study’s 
quality of reporting (10 items), ex-
ternal validity (3 items), internal va-
lidity or bias (7 items), confounding 
variables (6 items), power (1 item), 
and a global score (1 item assessing 
the rater’s overall impression of the 
quality of a paper) and has a pos-
sible total score of 42 (correspond-
ing to the maximum quality score 
of 100%). Scores below 50% were 
considered weak, those between 50% 
and 69% were considered fair, scores 
of 70–79% were good, and scores of 
80–100% were very good. We used 
a Mann-Whitney U test to compare 
quality scores between sensitive and 
nonsensitive outcomes, because 
there may be a relationship between 
the methodological quality of the 
included studies and the success of 
their respective interventions.
Medication adherence was re-
ported in the individual groups of 
the studies at baseline and end of 
study. Whenever feasible, the per-
centage of participants with con-
trolled BP at the end of the study 
and the corresponding odds ratio 
were mentioned. In each study, BP 
was classified as controlled using the 
national or international guidelines 
applicable at the time of the study. 
Because of the substantial differences 
among selected studies in terms of 
the various methods that were used 
to measure adherence (e.g., prescrip-
tion refill data, pill count, compliance 
questionnaire, plasma drug level), we 
believed that pooling of the medica-
tion adherence results was inappro-
priate. A fixed-effects meta-analytic 
model was used to combine SBP and 
DBP results. However, only studies 
with extractable data and that had 
a contemporary control group were 
included in the meta-analysis (i.e., 
subjects allocated to usual care [con-
trol group] were treated during the 
same time period [contemporary] 
as the intervention group) to ensure 
that the only difference between the 
groups was the pharmacist interven-
tion under investigation.
We explored the potential for 
publication bias by using funnel 
plots and calculating the Begg– 
Mazumdar23 statistic. We examined 
the heterogeneity of outcomes us-
ing the chi-square test.24 All analyses 
were conducted with SPSS, version 
17.0 (SPSS Institute, Chicago, IL) 
and Comprehensive Meta-Analysis, 
version 2.0 (Biostat, Englewood, NJ), 
and the a priori level of significance 
was 0.05.
Results
Initially, 225 potential articles 
were identified. After assessing their 
titles and excluding those not men-
tioning any information pertinent 
to hypertension, BP, or medication 
adherence studies, 130 remained and 
their abstracts read. Of the 47 articles 
retrieved for full-text review, 32 were 
excluded for the following reasons: 
not an interventional study,25-27 
studied participants with a different 
disease not relevant to review,28-32 did 
not include pharmacists in the study 
interventions,33 presented pharma-
ceutical interventions and outcomes 
investigating neither adherence nor 
BP,34-37 presented pharmaceutical 
interventions and outcomes inves-
tigating BP but not adherence,38-53 
investigated medication adherence 
outcome in the intervention group 
only and baseline adherence was 
not measured,54 and not studies but 
reviews.13,55 A total of 15 articles were 
included as full-text in our systematic 
review.14-20,56-63
Table 1 details some character-
istics of the included studies. One 
study tested different interven-
tions in three distinct intervention 
groups.16 In this study the authors 
attributed the simplest interven-
tion (provider education) to the 
control group and the remaining 
interventions (“provider education 
and alert” and “provider education 
and alert and patient education”) to 
two intervention groups. Another 
study included two pharmacist-
intervention groups, designated as 
a high-intensity intervention and 
a low-intensity intervention. We 
considered the low-intensity group, 
in which the only pharmacist inter-
vention was measurement of BP and 
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patient counseling to contact their 
physician whenever BP was above 
normal, as the control group. 
Medication management, educa-
tional interventions directed to the 
patient, and more-frequent follow-
up appointments or contacts were 
the most frequently used pharma-
cist interventions. The number of 
pharmacist interventions per study 
ranged from two to five. After BP val-
ues and medication adherence out-
comes, which were evaluated in all 
tudies, patient quality of life was the 
Table 1.
Characteristics of Studies Evaluating Pharmacists’ Interventions in Hypertension Treatmenta
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aMedication adherence and blood pressure were measured in all studies. Other measured outcomes included quality of life, self-measurement of blood pressure, 
alcohol moderation, exercise, salt restriction, smoking cessation, number of antihypertensive drugs, adverse drugs effects, hypertension-related knowledge, patient 
satisfaction, resource utilization, low-density-lipoprotein cholesterol concentration, and intensification of antihypertensive regimen.
bRCT = randomized clinical trial, SGCT = single-group clinical trial.
cIn all studies, pharmacists’ interventions included medication management (e.g., drug therapy monitoring or adjustment, simplification of antihypertensive regimens, 
resolution of adverse drug reactions). A = educational interventions directed to the patient (e.g., hypertension education, lifestyle education and counseling), B = 
scheduling more-frequent follow-up appointments or contacts, C = educational interventions and alerts directed to health care professionals, D = providing improved 
administration systems (e.g., medication event monitoring system, blister packs), E = instituting self-monitoring and recording of blood pressure, including education, 
encouragement, and validating blood pressure monitor, F = providing medication reminders, including education and counseling tips (adherence aid tools) and 
appointment reminders (e.g., telephone based, computer based), G = pharmacist clinical visit attendance.
dInteraction in the control group occurred a mean of 4.9 times in 12 months.
eInteraction in the control group occurred at baseline and at the midpoint and end of the study.
fInteraction in the control group occurred with the same frequency as in the intervention group.
gInteraction in the control group occurred a mean ± S.D. of 5.5 ± 1.3 times in 9 months.
hPatients at baseline served as their own controls.
iInteraction in the control group occurred at baseline and at the end of the study.
jInteraction in the control group occurred 4 times in 9 months.
kInteraction in the control group occurred 3 times in 3 months.
most evaluated outcome, present in 
6 of the 15 included studies.14,18-20,60,62
Table 1 also details the pharmacist– 
patient interaction in control and 
intervention groups of included 
studies. The most common fre-
quency of pharmacist–patient in-
teraction in the intervention group 
was between monthly and every 
two months, and the purpose of the 
interaction was to provide pharma-
cist interventions. The pharmacist–
patient interaction in the control 
group involved mostly baseline, 
intermediate, and endpoint assess-
ment of described outcomes.
Article quality scores, sample 
size, duration of follow-up, losses to 
follow-up, and outcomes sensitive to 
pharmacist interventions are shown 
in Table 2. The mean ± S.D. article 
quality score was 67.5% ± 10.6% 
(range, 50–76%), which was consid-
ered fair. The mean ± S.D. sample 
size was 218.7 ± 331.7 patients (me-
dian, 111 patients; range, 26–1341 
patients). The follow-up period of 
the studies evaluated ranged from 
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two weeks to 12 months, with an av-
erage duration of 6.7 ± 10.6 months. 
Losses to follow-up ranged from 
3.4% to 48.5% (mean ± S.D., 18.9% 
± 15.3%). Article quality scores did 
not increase from 2000 to 2008 (y 
= 596.848 – 0.264x, r2 = 0.006, p = 
0.790, where y = article quality score 
and x = publication year). Sixty-one 
percent of the outcomes (28/46) were 
categorized as sensitive to the phar-
macist interventions.
Effect on medication adherence 
and BP control. Adherence was mea-
sured in different ways, including 
self-report (through questionnaire 
or direct questioning), pill counts, 
analysis of prescription refill data, 
and plasma levels of hydrochlorothi-
azide. Various criteria for adherence 
were used in the studies, making a 
pooled analysis inappropriate (Table 
3). Baseline medication adherence 
to antihypertensive drugs ranged 
from 35% to 88.6%, and medication 
adherence at study end ranged from 
50% to 95.8%, which points to an 
increase in medication adherence 
due to pharmacist interventions. 
In fact, 7 of 16 intervention groups 
demonstrated a significant improve-
ment in medication adherence when 
compared with the control groups. 
Differences in adherence rates at 
study end between pharmacist inter-
vention groups and control groups 
varied from 8% to 58% in studies 
with positive sensitive outcomes. 
Although 5 studies revealed that 
pharmacist interventions had a nega-
tive effect on patients’ treatment ad-
herence compared with the control 
group, which ranged from –1% to 
–8%, these negative results were not 
significant. One study found an ab-
normally high increase in treatment 
adherence rate (increase of 58% from 
baseline); however, no comparison 
group was used in this study, and the 
follow-up period was only two weeks. 
The correlation between article qual-
ity scores and impact of pharmacist 
interventions was –0.680 (p = 0.004) 
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servation suggests that higher quality 
scores are associated with a lesser ef-
fect on medication adherence. All of 
the 4 single-group controlled trials 
evaluated (with no contemporary 
comparison control group) reported 
a significant increase in medication 
adherence. The remaining 3 stud-
ies, which were RCTs, that reported 
a significant increase in medica-
tion adherence had more-frequent 
follow-up with the intervention 
group. Six other studies also adopted 
more-frequent follow-up without 
a significant increase in medication 
adherence. In 5 of these 6 studies, the 
endpoint adherence rate was high 
(>80%) in the control group, pos-
sibly making it difficult to achieve a 
further increase in the intervention 
group. Indeed, all 7 studies with a 
high adherence rate at study end-
point (>80%) in the control group 
Table 4.
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aSBP = systolic blood pressure, DBP = diastolic blood pressure, OR = odds ratio, CI = confidence interval, NR = not reported, HI = high income, LI = low income, 
NS = not significant.
bProvider education and alert intervention group.
cProvider education and alert and patient education intervention group. 
found that pharmacist interventions 
had a nonsignificant effect on medi-
cation adherence. All other stud-
ies but 1 revealed that pharmacist 
interventions had a positive effect 
on medication adherence, with a 
mean difference in adherence rates at 
endpoint between intervention and 
control groups of 22.2%.
Likewise, various criteria were 
used to report BP outcome, making 
it inappropriate to pool data from all 
included studies, though the range 
of results from individual studies are 
presented (Table 4). Of the 15 studies 
evaluated, 2 did not measure SBP or 
DBP, 7 studies described a significant 
improvement in both SBP and DBP, 
4 described a significant improve-
ment in SBP alone, and 1 study noted 
a significant improvement in DBP 
alone. Significant improvements in 
SBP and DBP ranged from –5.0 to 
–18.6 mm Hg and from –1.0 to –12.2 
mm Hg, respectively.
Three of the included studies did 
not describe the percentage of par-
ticipants with controlled BP at the 
end of the study. Seven studies found 
a significant increase in the percent-
age of participants with controlled 
BP at the end of the study when 
comparing intervention and control 
groups, which ranged from 17.5% 
to 51.0%. The authors of each study 
classified BP as controlled using the 
national or international guidelines 
applicable at the time of the study 
(in most studies, BP was considered 
controlled when SBP was < 140 mm 
Hg and DBP was < 90 mm Hg). In 
11 studies, we were able to calculate 
the odds ratio for the rate of patients 
achieving controlled BP at endpoint 
in the intervention group compared 
with the control group, and a range 
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of 1.46–12.18 was obtained, with a 
mean ± S.D. value of 4.43 ± 3.6.
Of the 7 studies that found a sig-
nificant improvement in both SBP 
and DBP, 42.9% were single-group 
controlled trials (with no contem-
porary comparison control group). 
Thus, we analyzed the correlation 
between article quality scores and the 
impact of pharmacist interventions 
on SBP and DBP. This correlation 
was –0.599 (p = 0.018) for SBP and 
–0.659 (p = 0.007) for DBP. These 
observations suggest that higher 
quality studies are associated with a 
lesser effect on BP control.
A total of 8 controlled trials were 
included in the meta-analysis (Table 
5). The remaining 7 studies were not 
included because the data were not 
extractable56,58,60 and a comparison 
contemporary control group was not 
used.18-20,57 
Effects on SBP. Sensitive out-
comes were reported in 11 of 13 
studies evaluating SBP. It was pos-
sible to include only 8 studies for the 
meta-analysis of SBP outcomes. A 
funnel plot (data not shown) did not 
rule out the possibility of publication 
bias; therefore, we applied the trim-
and-fill method,64 which increased 
the difference in SBP change between 
intervention and placebo from 4.9 to 
5.6 mm Hg (p < 0.001). However, the 
Begg–Mazumdar23 statistic was very 
small and nonsignificant (t < 0.001, 
p = 1.0). The Q statistic for hetero-
geneity of effects was not significant 
(c2 = 0.741, p = 0.99); therefore, we 
considered the study results to be 
combinable.
The meta-analytic mean ± S.D. 
baseline and endpoint SBPs in the 
pharmacist intervention group were 
153.0 ± 4.7 and 130.9 ± 4.6 mm Hg, 
respectively, producing a clinical 
and statistical weighted difference 
of –19.4 ± 3.5 mm Hg (p < 0.001). 
A significant difference was also ob-
served in the mean ± S.D. SBP from 
baseline (151.3 ± 4.9 mm Hg) to 
endpoint (137.5 ± 6.4 mm Hg) in the 
control group, with a meta-analytic 
difference of –11.3 ± 4.2 (p = 0.007). 
Meta-analytic differences from base-
line to endpoint of both groups were 
calculated and are presented in Fig-
ure 1. The meta-analytic mean ± S.D. 
difference in SBP from baseline to 
endpoint between intervention and 
control groups was –4.9 ± 0.9 mm Hg 
(p < 0.001).
Effects on DBP. Sensitive outcomes 
were reported in 8 of 13 studies evalu-
ating DBP. It was possible to include 
only 7 studies for the meta-analysis 
of DBP evaluation. The funnel plot 
was similar to that for SBP (data 
not shown). Use of the trim-and-fill 
method increased the difference 
between intervention and placebo 
from 2.6 to 3.3 mm Hg (p < 0.001). 
However, the Begg–Mazumdar23 sta-
tistic did not detect publication bias 
(t = –0.09, p = 0.76). The Q statistic 
found no heterogeneity of effects 
(c2 = 2.23, p = 0.90), so the results 
were considered combinable.
The meta-analytic mean ± S.D. 
baseline and endpoint DBPs in the 
pharmacist intervention group were 
82.6 ± 4.3 and 74.6 ± 3.8 mm Hg, 
respectively, producing a clinical and 
statistical weighted difference of –8.8 
± 2.9 mm Hg (p = 0.002). However, 
a nonsignificant difference was ob-
served in DBP from baseline (81.7 ± 
4.3 mm Hg) to endpoint (76.9 ± 4.2 
mm Hg) in the control group, with a 
meta-analytic difference of –4.9 ± 3.0 
mm Hg (p = 0.103). Meta-analytic 
differences from baseline to endpoint 
of both groups were calculated and 
are presented in Figure 1. Pharmacist 
intervention reduced the DBP of the 
intervention group an additional 2.6 
± 0.9 mm Hg when compared with 
the control group (p < 0.001).
Discussion
The majority of the studies in-
cluded in our analysis were RCTs. 
Although the mean quality of these 
RCTs was considered good (qual-
ity score, 72.3%), the mean quality 
of all the studies evaluated was fair 
(quality score, 67.5%). It is not fea-
sible to blind hypertensive patients 
in pharmaceutical intervention 
models, as this process of blind-
ing is assessed in one item of the 
Downs and Black22 quality checklist. 
By removing this item, the average 
quality of all articles included would 
increase to over 70%. However, 6 
studies in which patients were not 
randomized to intervention groups, 
which are assessed by two items of 
the Downs and Black quality check-
list, prevented a further increase of 
the overall quality score.
Although 88% of the interven-
tions tested (14 of 16 in 15 studies) 
resulted in significant improvements 
in treatment outcomes (SBP, DBP, 
or percentage of participants with 
controlled BP at the end of the study), 
only 44% of the interventions (7 of 
16 in 15 studies) were associated with 
significant increases in medication 
adherence. These results were higher 
than those obtained by Machado et 
al.,13 who found that 76.6% and 38.5% 
of studies analyzed reported improve-
ment in treatment outcomes and in 
medication adherence, respectively, 
though they did not address BP con-
trol specifically. Differences obtained 
in the systematic review of Machado 
et al.13 and in our review reflect a 
trend toward improved medication 
adherence and treatment outcomes 
obtained with the most recent studies, 
which included more interventions 
involving physician–pharmacist col-
laboration.14,16-20 In both systematic 
reviews, all studies that found a sig-
nificant increase in medication adher-
ence also demonstrated a significant 
improvement in treatment outcomes, 
revealing that medication adherence 
is a key factor (though not the only 
one) for achieving BP control.
Drug therapy adjustments may 
have contributed to improvements in 
BP control in studies where medica-
tion adherence rates did not signifi-
cantly change. Some studies suggest-
ed that antihypertensive medications 
are frequently not intensified when 
BP remains uncontrolled (clinical in-
Practice rePorts Pharmacist interventions


























































































































































































































































































































































































   
   






































































































































































































   
   
 . 
. . 78 34 11
7 27 61 95
0
23
3 76 78 34 11



















































































































   
   









































































































   
   



















































































































































































































































































































































































Practice rePorts Pharmacist interventions
250 Am J Health-Syst Pharm—Vol 68  Feb 1, 2011
ertia).65,66 By addressing suboptimal 
medication regimens, pharmacists 
may have contributed to changing 
unsuccessful regimens, searching for 
those regimens that would be more 
likely to succeed. However, it is also 
possible that the several methods 
used to measure adherence, some 
of which were unreliable, may have 
contributed to the inconsistency in 
adherence-rate differences between 
control and intervention groups. 
Large high-quality trials that use 
reliable methods of measuring ad-
herence are needed to investigate the 
relationship between adherence and 
BP reduction.
SBP and DBP were definitely 
sensitive to pharmacist interven-
tions, as we found that baseline to 
endpoint reductions in these out-
comes were significantly influenced 
in intervention groups compared 
with control groups. These results 
also differ from those obtained 
by Machado et al.,13 whose review 
showed that only SBP was sensitive 
to pharmacist interventions. 
Almost all the interventions that 
were effective for medication adher-
ence or BP control improvements 
were complex, including combina-
tions of medication management, 
educational programs directed at 
the patient, scheduling of more-
frequent follow-up appointments, 
medication reminders, counseling, 
self-monitoring of BP, and other 
forms of additional supervision or 
attention. We were not able to find 
a pattern of types or numbers of 
interventions that predicted success. 
Methods for improving antihyper-
tensive adherence and BP control 
were generally labor-intensive (and 
therefore expensive) and not pre-
dictably effective. However, many 
intervention programs did lead to 
improved adherence or treatment 
outcomes. In 10 studies, we were able 
to calculate the odds ratio for the rate 
of patients achieving targeted BP at 
endpoint in the intervention group 
when compared with the control 
group, and a range of 1.46–12.18 was 
obtained, with a mean ± S.D. value 
of 4.43 ± 3.6. These values imply 
that achieving controlled BP at the 
end of the study was more likely in 
the intervention group and are in 
accordance with the values obtained 
by Carter et al.67 In addition, stud-
ies with the largest effect sizes (i.e., 
the largest reductions in SBP or 
DBP from baseline to endpoint) had 
higher mean baseline SBP and DBP 
values (Table 5). Thus, the clinical 
impact of pharmacist interventions 
in hypertensive patients is expected 
to be more pronounced in high-risk 
patients. Moreover, it is possible 
that some pharmacist intervention 
programs put more emphasis on bet-
ter communication and empathetic 
reinforcement, as these actions build 
trust, are potent motivators, and tend 
Figure 1. Meta-analytic differences in improvement of systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) (mm Hg) between patients receiving a pharmacist 
intervention and patients in control groups. Negative estimates favor the intervention 
group over the control group in the reduction of SBP or DBP in hypertensive patients. The 
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to improve outcomes.1 Motivation 
improves when patients have positive 
experiences with and trust in their 
health care staff. More studies are 
needed to assess the role of commu-
nication and empathetic reinforce-
ment skills of pharmacists and other 
health care personnel on patient mo-
tivation and outcomes improvement.
Our study had several limitations. 
Comparing the different studies 
included in this review was difficult 
due to marked heterogeneity in 
terms of research designs, interven-
tions, duration of follow-up, meth-
ods to measure medication adherence, 
and reporting of clinical outcomes. 
Some studies demonstrated poor 
methodological quality, particularly 
with regard to the presence of a con-
temporary comparison control group, 
randomization, blinding of outcomes 
assessment, and losses to follow-up. In 
two studies, the duration of follow-up 
was too short (three months or less), 
which is considered inadequate to 
classify adherence rates accurately25,68 
and to demonstrate persistent positive 
clinical findings.69
Adherence was measured and cal-
culated in various ways, which made 
a pooled analysis inappropriate. For 
example, in one study,58 the baseline 
adherence measured by the Morisky 
et al.70 questionnaire was 83% and 
68% in the control and intervention 
groups, respectively. When using 
refill-data analysis, the baseline ad-
herence of the same patients was 93% 
and 98% in the control and interven-
tion groups, respectively. Medica-
tion adherence was usually assessed 
unblinded to allocation status, which 
constitutes a potential source of bias. 
Without an agreement on criteria to 
measure and define medication ad-
herence, it is not surprising that the 
effect of most interventions on ad-
herence and BP was variable, making 
it difficult to examine the relation-
ship between medication adherence 
and subsequent BP control. 
We were not able to include sev-
eral studies in our meta-analysis of 
SBP and DBP in the intervention 
and control groups, because some 
studies either did not report these 
data or did not use a comparison or 
control group. One other limitation 
is based on the quality of pharmacist 
interventions made. It is possible that 
the same pharmacist intervention 
led to different results, depending on 
the empathetic reinforcement and 
motivation provided by the health 
care personnel that have contact with 
hypertensive patients. Therefore, 
some degree of variation of results 
is expected in clinical pharmacy 
practice. Another limitation is our 
literature search was conducted us-
ing the main electronic databases 
freely available in our research cen-
ter, leaving out important databases 
like International Pharmaceutical 
Abstracts and EMBASE. We tried 
to circumvent this limitation by 
hand searching bibliographies of 
all retrieved articles to identify ad-
ditional publications of pharmacist 
interventions on patient medica-
tion adherence. Finally, a chance of 
publication bias cannot be ruled out 
based on funnel plot analyses and 
the trim-and-fill method, though 
our search criteria were intended to 
capture all published articles evaluat-
ing pharmacist interventions on both 
antihypertensive medication adher-
ence and BP control. Publication bias 
occurs when authors are more likely 
to submit, or editors accept, positive 
rather than null (negative or incon-
clusive) results. A search performed 
for unpublished data would have 
helped to minimize the occurrence of 
publication bias.
Conclusion
A literature review and meta-
analysis showed that pharmacist in-
terventions can significantly improve 
medication adherence, SBP, DBP, 
and BP control in patients with es-
sential hypertension. Interventions 
were complex and multifaceted and 
included medication management in 
all analyzed studies.
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